載入...
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
BACKGROUND: The combination of everolimus and the imidazoquinoline derivative, BEZ235 (dactolisib), a dual PI3K/mTOR inhibitor, demonstrated synergy in a preclinical model. OBJECTIVE: To establish clinical feasibility, a phase Ib dose-escalation trial investigating safety and pharmacokinetics of thi...
Na minha lista:
| 發表在: | Target Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5447332/ https://ncbi.nlm.nih.gov/pubmed/28357727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-017-0482-9 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|